Seeking Alpha

Recent IPO Clovis Oncology (CLVS -9.8%) takes a hit after posting a $14.9M Q4 loss, despite...

Recent IPO Clovis Oncology (CLVS -9.8%) takes a hit after posting a $14.9M Q4 loss, despite showing improvement over the prior year period. Bottom line margins were hit as R&D expenses nearly doubled due to the expanded development activities for its CO-101 and CO-1686 drugs, as well as the in-licensing of Rucaparib from Pfizer in mid 2011.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)